



SHUKRA

PHARMACEUTICALS LTD.

August 13, 2025

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

Scrip Code: 524632

Dear Sir/Madam,

Sub: Outcome of the meeting of the Board of Directors held on Wednesday, August 13, 2025.

Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the at their meeting held on today i.e. Wednesday, August 13, 2025 at the Registered Office of the Company *inter-alia* has, considered and approved the following: -


1. Un-Audited Financial Results of the Company for the First Quarter ended June 30, 2025, along with the Auditors' Limited Review Reports in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations.
2. Reviewed the business of the company

The Board Meeting commenced at 03.00 p.m. and concluded at 3.30 p.m.

You are requested to take the above information on records and disseminated the same on your respective websites.

Thanking you,
Yours faithfully

For Shukra Pharmaceuticals Limited


Bhoomiben Patel
Director
DIN: 08316893

Encl.: a/a

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

SHUKRA PHARMACEUTICALS LIMITED

CIN: L24231GJ1993PLC019079

3rd Floor, Dev House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380003

Email : info@shukrapharmaceuticals.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

Rs. In Lakhs (Except EPS)

Sr. No.	Particulars	QUARTER ENDED			Year Ended
		30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
1	Income from Operations				
I	Revenue from Operations	539.11	1,326.98	317.80	3,258.73
II	Other Income	110.97	146.53	71.76	420.67
	Total Income from Operations (I+II)	650.08	1,473.50	389.56	3,679.39
2	Expenses				
	(a) Cost of materials consumed	(124.85)	559.29	92.15	1,174.55
	(b) Changes in inventories of finished goods, and work-in-progress and stock in trade	201.88	(383.03)	(90.48)	(363.38)
	(c) Employee Benefit Expenses	182.49	175.02	138.27	611.01
	(d) Finance Cost	26.81	27.08	6.17	59.49
	(e) Depreciation & Amortisation Expenses	78.72	94.39	66.51	300.49
	(f) Other Expenses	147.71	243.74	97.27	563.57
	Total Expenses	512.78	716.49	309.89	2,345.73
3	Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-2)	137.30	757.01	79.67	1,333.66
4	Exceptional Items	-	-	-	-
5	Profit / (Loss) before Extra ordinary items and Tax (3-4)	137.30	757.01	79.67	1,333.66
6	Extra ordinary items	-	-	-	-
7	Net Profit / (Loss) from Ordinary Activities before Tax(5-6)	137.30	757.01	79.67	1,333.66
8	Tax Expenses				
	I. Current Tax	40.59	218.09	26.60	362.36
	II. Deferred Tax	(6.24)	(0.27)	4.54	13.78
	III. Tax of Earlier Year	-	-	-	-
	IV. MAT Credit Entitlement	-	-	-	-
9	Net Profit / (Loss) for the Period (7-8)	102.96	538.64	48.53	957.51
10	Other Comprehensive Income (net off Tax)	-	-	-	-
	Remeasurement of defined benefit plans	-	1.08	-	1.08
	Prior Period Adjustments & Expenses	-	-	-	-
11	Total Comprehensive Income for the period (9+10)	102.96	539.72	48.53	958.59
12	Paid up Equity Share Capital	4,378.79	4,378.79	4,378.79	4,378.79
13	Face Value of Equity Shares	1.00	1.00	10.00	1.00
14	Earnings per Share (of Re. 10/- each) :				
	(a) Basic-Rs	0.02	0.12	0.11	0.22
	(b) Diluted-Rs	0.02	0.12	0.11	0.22

NOTES:

- The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 13th
- The Unaudited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015.
- The Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the
- During the quarter ended 30th June, 2025, 2 complaints were received out of that 2 complaints were disposed off at the end of the quarter.
- The figures for the previous period/year have been regrouped /reclassified, wherever necessary.
- The Company is operating in single segment, so above results are for single segment only.



For and on behalf of Board of Directors of
Shukra Pharmaceuticals Limited

Dakshesh
Rameshchandra Shah

Dakshesh Shah
Managing Director
DIN : 00561666

CIN : L24231GJ1993PLC019079


Place: Ahmedabad
Date: 13/08/2025

INDEPENDENT AUDITOR'S REVIEW REPORT on Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
SHUKRA PHARMACEUTICALS LIMITED
Ahmedabad

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SHUKRA PHARMACEUTICALS LIMITED** (the "Company"), for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR MAAK and Associates
[Firm Registration No.135024W]
Chartered Accountants


Marmik Shah
Partner
Mem. No. 133926

Place : Ahmedabad
Date : 13th August, 2025
UDIN : 25133926 BMJHCS5047.